Dorsey & Whitney advised Rezolute, while Paul Hastings advised Jefferies and Cantor as joint book-running managers in the offering. Rezolute, Inc. (Nasdaq: RZLT) completed its underwritten...
Rezolute’s $60 Million Common Stock Offering
Vaxart’s $40 Million Common Stock Offering
Thompson Hine advised Vaxart, while Paul Hastings LLP advised Oppenheimer & Co. as the sole bookrunner in the offering. Vaxart, Inc. (Nasdaq: VXRT) announced an underwritten...
ProKidney’s Upsized Public Offering and Registered Direct Offering
Davis Polk & Wardwell advised ProKidney, while Paul Hastings advised Jefferies, J.P. Morgan, and Guggenheim Securities, as joint book-running managers, in the transaction. ProKidney Corp. (Nasdaq:...
Monte Rosa Therapeutics’ $100 Million Underwritten Public Offering
Goodwin Procter advised Monte Rosa Therapeutics, while Paul Hastings advised TD Cowen and Wedbush PacGrow, as joint book-running managers, in the offering. Monte Rosa Therapeutics, Inc....
GenSight Biologics’ PIPE Financing
Paul Hastings LLP advised Chardan Capital Markets and Invest Securities as joint global coordinators and bookrunners in the transaction. GenSight Biologics executed its private placement (PIPE)....
INOVIO Pharmaceuticals’ $36 Million Common Stock Offering
Cooley advised INOVIO Pharmaceuticals, while Paul Hastings LLP advised Oppenheimer & Co. and Citizens JMP as joint book running managers in the offering. INOVIO executed an...
Century Therapeutics’ $60 Million Private Placement
Paul Hastings LLP advised BofA Securities as the sole placement agent in the transaction. Century entered into a securities purchase agreement with a select group of...
Leap Therapeutics’ $40 Million Private Placement
Paul Hastings LLP advised J.P. Morgan Securities LLC as the exclusive placement agent in the transaction. Leap Therapeutics, Inc. (Nasdaq:LPTX) has entered into a securities purchase agreement with...
NervGen’s C$23 Million Bought Deal Financing
Paul Hastings LLP advised NervGen Pharma Corp. in the transaction. NervGen Pharma Corp. closed its public offering including the full exercise of the underwriters’ over-allotment option...
Evolus’ $50.0 Million Common Stock Offering
Paul Hastings LLP advised Leerink Partners and Stifel as joint bookrunning managers in the offering. Evolus, Inc. (Nasdaq: EOLS) announced the pricing of its underwritten offering...
Skye Bioscence’s $40 Million Private Placement Equity Financing
Paul Hastings LLP advised Piper Sandler and Co. as lead placement agent, and Oppenheimer & Co. as placement agent in the transaction. Skye Bioscience, Inc. (OTCQB:...
Lexeo Therapeutics’ $95 Million Private Placement
Paul Hastings LLP advised J.P. Morgan and Leerink Partners as co-lead placement agents, and Stifel co-placement agent, in the transaction. Lexeo Therapeutics, Inc. (Nasdaq: LXEO) has entered...